Avalo (AVTX) CMO Doyle Mittie Exercises Options, Sells 1,000 Shares

What Happened
Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), exercised 1,000 stock options at $12.65 per share (total cost $12,650) and sold 1,000 shares in an open-market transaction at $20.00 per share (gross proceeds $20,000) on August 17, 2026. The Form 4 also reports a related conversion/disposition of 1,000 derivative shares at $0, which is tied to the option exercise reporting.

Key Details

• Transaction date: 2026-08-17. Exercise: 1,000 shares @ $12.65 (Acquired) = $12,650. Sale: 1,000 shares @ $20.00 (Disposed) = $20,000. Derivative conversion/disposition: 1,000 @ $0 reported.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: Trades were executed under a Rule 10b5-1 trading plan adopted Nov 13, 2025 (F1). The options have a staggered vesting schedule (25% vested July 15, 2025; remainder monthly over the next 3 years) (F2).
• Filing timeliness: Form filed 2026-08-19 for the 2026-08-17 transactions — appears timely (within standard Form 4 reporting window).

Context

• This sequence (exercise followed by an open-market sale of the same number of shares) is consistent with exercising stock options and immediately selling the resulting shares; the reported $0 derivative disposition likely reflects the conversion/settlement step tied to the exercise.
• These transactions were made pursuant to a pre-established 10b5-1 plan, which typically schedules trades in advance and is considered routine trading rather than a discretionary, immediate insider decision.
• No indication in the provided data that the reporting person is a 10% owner; this appears to be routine executive option exercise and partial sell-down activity.